B CELL MALIGNANCIES

This trial tests a new type of immunotherapy called bi-specific CAR-T cells that target two proteins, CD19 and CD70, found on certain B cell cancers. The treatment involves collecting a patient's own immune cells, modifying them to recognize and attack cancer cells, and infusing …

This study tests a new treatment called 4SCAR19 cells for people with B-cell cancers that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better find and attack cancer cells. The trial aims to check safety…

This study tests a new type of immunotherapy called bi-specific CAR-T cells that target two proteins, CD19 and CD22, on the surface of B cell cancer cells. The treatment involves infusing these engineered immune cells into patients whose B cell malignancies have returned or not r…

This study tests a new type of immunotherapy called bi-specific CAR-T cells that target two proteins, CD19 and CD79b, found on B cell cancers. The therapy involves collecting a patient's own immune cells, modifying them to recognize and attack cancer cells, and infusing them back…

This trial tests a combination of genetically modified immune cells (CAR-T cells) that target CD19 plus another protein on B-cell cancers. The goal is to improve treatment for patients whose cancer has returned or not responded to standard therapy. The study enrolls 100 participa…

This early-phase trial tests a new 'universal' CAR T cell therapy (4SCAR19U) for people with B cell cancers that have come back or not responded to treatment. The therapy uses donor-derived immune cells engineered to target CD19 on cancer cells. The study aims to check safety and…

This study tests whether adding emavusertib to a standard targeted therapy (zanubrutinib) can improve outcomes for people with chronic lymphocytic leukemia (CLL) and other B-cell cancers. About 108 adults with CLL who have already received some treatment will take both drugs. The…

This study tests an experimental drug called AZD5492 in people with B-cell cancers (like lymphoma or leukemia) that have come back or not responded to at least two prior treatments. The drug works by helping the body's T cells attack cancer cells. The trial will check safety, sid…

This early-phase trial is testing an experimental mRNA-based drug that turns the body's own cells into cancer fighters. The drug targets CD19, a protein found on certain blood cancer cells. Researchers will enroll 47 adults with B-cell lymphoma or leukemia who have run out of sta…

This study tests a new treatment called SHB-04-CD22, which uses a patient's own immune cells (T-cells) engineered to find and attack cancer cells that have a protein called CD22. It is for children and adults (ages 1-80) with B-cell cancers that have come back or not responded to…